Sirolimus-Eluting Stents Versus Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction: 9-Month Angiographic and Intravascular Ultrasound Results and 12-Month Clinical OutcomeResults From the MISSION! Intervention Study
Bas L. van der Hoeven, MD*,
Su-San Liem, MD*,
J. Wouter Jukema, MD, PhD*,1,
Navin Suraphakdee, MD*,
Hein Putter, MSc, PhD ,
Jouke Dijkstra, MSc, PhD ,
Douwe E. Atsma, MD, PhD*,
Marianne Bootsma, MD, PhD*,
Katja Zeppenfeld, MD, PhD*,
Pranobe V. Oemrawsingh, MD, PhD*,
Ernst E. van der Wall, MD, PhD* and
Martin J. Schalij, MD, PhD*,*
* Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
Department of Medical Statistics and Bio-Informatics, Leiden University Medical Center, Leiden, the Netherlands
Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Patient Flow Chart, Enrollment, and Outcomes
BMS = bare metal stent; CAG = coronary angiography; IVUS = intravascular ultrasound; QCA = quantitative coronary angiography; SES = sirolimus-eluting stent; TLR = target lesion revascularization.
|
|
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Event Free and TVF Free Survival
(A) Kaplan-Meier estimates of survival free from any events among patients treated with BMS and those treated with SES. The event-free survival was significantly higher in the SES group than the BMS group (p = 0.01). (B) Kaplan-Meier estimates of survival free from target vessel failure (TVF) among patients treated with BMS and those treated with SES. The TVF free survival was significantly higher in the SES group than the BMS group (p = 0.02). Abbreviations as in Figure 1.
|
|
|
